News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
202 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39672)
2015 (44432)
2016 (38329)
2017 (37188)
2018 (39119)
2019 (51334)
2020 (57663)
2021 (58720)
2022 (53927)
2023 (42564)
2024 (37441)
2025 (33090)
2026 (21900)
Month
January (2433)
February (2866)
March (3029)
April (3115)
May (3356)
June (2725)
July (2286)
August (2090)
Day
1 (117)
2 (174)
3 (44)
5 (18)
6 (63)
7 (148)
8 (162)
9 (80)
10 (92)
12 (11)
13 (86)
14 (145)
15 (167)
16 (131)
17 (117)
19 (12)
20 (202)
21 (171)
22 (152)
23 (182)
24 (89)
26 (24)
27 (111)
28 (193)
29 (219)
30 (205)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Month
January
February
March
April
May
June
July
August
Day
1
2
3
5
6
7
8
9
10
12
13
14
15
16
17
19
20
21
22
23
24
26
27
28
29
30
Lung cancer
Merck’s early PD-1/VEGF data competitive in lung cancer, but Summit ‘looms large’
While Merck’s PD-1/VEGF asset appears to match the performance of Summit Therapeutics’ ivonescimab, the pharma’s Phase 1/2 readout in non-small cell lung cancer still leaves analysts with some questions moving into later-stage development.
April 20, 2026
·
2 min read
·
Tristan Manalac
Psychedelics
Trump throws support behind psychedelics with executive order
A new executive order could usher in psychedelics as the “key next wave” of mental health therapies, according to analysts at RBC Capital Markets.
April 20, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
UCB elevates epilepsy expertise with up to $1.15B Neurona takeover
The acquisition of Neurona will put UCB in both the epilepsy and cell therapy space, even as many of its fellow pharmas move away from the latter modality.
April 20, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program - April 20, 2026
April 20, 2026
·
2 min read
Press Releases
Kraig Biocraft Laboratories Advances Record Production and Begins Processing 1.8 Metric Tons of Recombinant Spider Silk Cocoons
April 20, 2026
·
4 min read
Press Releases
Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)
April 20, 2026
·
4 min read
Press Releases
Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit
April 20, 2026
·
5 min read
Press Releases
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
April 20, 2026
·
7 min read
Press Releases
Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer
April 20, 2026
·
4 min read
Press Releases
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
April 20, 2026
·
8 min read
Previous
11 of 21
Next
